(Reuters) -Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company’s treatment pipeline.

The latest setback comes after Sarepta’s top-selling gene therapy, Elevidys, was briefly pulled from the market in July following the death of three patients from acute liver failure. The stock has lost about 80% of its value this year.

The latest trial enrolled 225 patients aged 6 to 13 with Duchenne muscular dystrophy (DMD) and tested casimersen and golodirsen, which belong to a class of drugs called phosphorodiamidate morpholino oligomers, or PMOs, designed to help produce functional dystrophin protein.

“The failure of the … study exacerbates Sarepta’s woes in the DMD s

See Full Page